Kiniksa Pharmaceuticals, Ltd. (KNSA)
NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
收市：04:00PM EDT
收市後：
| 前收市價 | 20.19 |
| 開市 | 20.05 |
| 買盤 | 19.52 x 200 |
| 賣出價 | 19.57 x 300 |
| 今日波幅 | 19.53 - 20.50 |
| 52 週波幅 | 13.02 - 22.09 |
| 成交量 | |
| 平均成交量 | 388,422 |
| 市值 | 1.385B |
| Beta 值 (5 年，每月) | 0.32 |
| 市盈率 (最近 12 個月) | 150.23 |
| 每股盈利 (最近 12 個月) | 0.13 |
| 業績公佈日 | 2024年7月23日 - 2024年7月29日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 30.80 |
Insider MonkeyKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript April 23, 2024 Kiniksa Pharmaceuticals, Ltd. beats earnings expectations. Reported EPS is $-0.00025, expectations were $-0.14. KNSA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for […]
ZacksKiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of -78.57% and 4.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ZacksArcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.
